# PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

> **NCT02367807** · — · COMPLETED · sponsor: **Philadelphia Fight** · enrollment: 50 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Emtricitabine and tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT02367807
- **Lead sponsor:** Philadelphia Fight
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367807, "PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02367807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*